Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apimostinel With or Without Cognitive Training in Major Depressive Disorder
NCT06400121Phase 2Recruiting
- Sponsor
- Rebecca Price
- Start
- Oct 2024
- Primary completion
- Mar 2029
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apimostinel in major depressive disorder (MDD), sponsored by Rebecca Price. Started Oct 2024; status: recruiting.
02
Drugs
apimostinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06400121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06400121.